Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers.
Body mass index
Gout
Inosine
Purine
Urate
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
04 11 2020
04 11 2020
Historique:
received:
04
07
2020
accepted:
18
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
22
6
2021
Statut:
epublish
Résumé
High body mass index (BMI) is strongly associated with hyperuricaemia. It is unknown whether overweight and obesity influences serum urate primarily through increased urate production or reduced renal clearance of uric acid. The aim of this study was to determine the influence of BMI on the response to inosine, a purine nucleoside that functions as an intermediate in the purine salvage and degradation pathways. Following an overnight fast, 100 healthy participants without gout attended a study visit. Blood and urine samples were taken prior to and over 180 min after 1.5 g oral inosine. Serum urate and fractional excretion of uric acid (FEUA) were analysed according to high BMI (≥ 25 kg/m Participants in the high BMI group (n = 52, mean BMI 30.8 kg/m In a fasting state, people with high BMI have elevated serum urate levels but similar FEUA values compared with those with low/normal BMI. Following a purine load, those with high BMI have an attenuated renal excretion of uric acid. These data, using an experimental method to dynamically assess human urate handling, suggest that people with high BMI have a higher renal capacity for uric acid reabsorption when fasted and following a dietary purine intake have reduced renal clearance. Australia and New Zealand Clinical Trials Registry, ACTRN12615001302549 , date of registration 30 November 2015.
Sections du résumé
BACKGROUND
High body mass index (BMI) is strongly associated with hyperuricaemia. It is unknown whether overweight and obesity influences serum urate primarily through increased urate production or reduced renal clearance of uric acid. The aim of this study was to determine the influence of BMI on the response to inosine, a purine nucleoside that functions as an intermediate in the purine salvage and degradation pathways.
METHODS
Following an overnight fast, 100 healthy participants without gout attended a study visit. Blood and urine samples were taken prior to and over 180 min after 1.5 g oral inosine. Serum urate and fractional excretion of uric acid (FEUA) were analysed according to high BMI (≥ 25 kg/m
RESULTS
Participants in the high BMI group (n = 52, mean BMI 30.8 kg/m
CONCLUSIONS
In a fasting state, people with high BMI have elevated serum urate levels but similar FEUA values compared with those with low/normal BMI. Following a purine load, those with high BMI have an attenuated renal excretion of uric acid. These data, using an experimental method to dynamically assess human urate handling, suggest that people with high BMI have a higher renal capacity for uric acid reabsorption when fasted and following a dietary purine intake have reduced renal clearance.
TRIAL REGISTRATION
Australia and New Zealand Clinical Trials Registry, ACTRN12615001302549 , date of registration 30 November 2015.
Identifiants
pubmed: 33148335
doi: 10.1186/s13075-020-02357-y
pii: 10.1186/s13075-020-02357-y
pmc: PMC7641836
doi:
Substances chimiques
Uric Acid
268B43MJ25
Inosine
5A614L51CT
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
259Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK114091
Pays : United States
Références
Rheumatology (Oxford). 2008 May;47(5):713-7
pubmed: 18390895
Metabolism. 2001 Jun;50(6):621-6
pubmed: 11398134
Am J Physiol. 1995 Jan;268(1 Pt 1):E1-5
pubmed: 7840165
J Altern Complement Med. 2009 Jun;15(6):619-25
pubmed: 19425822
Arthritis Rheumatol. 2020 Jan;72(1):157-165
pubmed: 31486212
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1290-4
pubmed: 22132989
J Clin Endocrinol Metab. 1994 Jan;78(1):25-9
pubmed: 8288709
Rheumatology (Oxford). 2012 May;51(5):901-9
pubmed: 22253023
Rheumatology (Oxford). 2010 Dec;49(12):2391-9
pubmed: 20805117
JAMA Neurol. 2014 Feb;71(2):141-50
pubmed: 24366103
RMD Open. 2017 Apr 11;3(1):e000424
pubmed: 28951782
Ann Rheum Dis. 2013 Nov;72(11):1868-73
pubmed: 23349133
Arthritis Res Ther. 2015 Sep 22;17:263
pubmed: 26391224
Am J Hum Genet. 2008 Dec;83(6):744-51
pubmed: 19026395
JAMA. 1991 Dec 4;266(21):3008-11
pubmed: 1820474
Nat Commun. 2020 Jun 2;11(1):2767
pubmed: 32488095
Nature. 2002 May 23;417(6887):447-52
pubmed: 12024214
Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F826-F834
pubmed: 28679589
Ann Rheum Dis. 2010 Sep;69(9):1677-82
pubmed: 20472590